XBiotech (XBIT) Total Liabilities (2014 - 2026)
XBiotech (XBIT) posted quarterly Total Liabilities of $9.7 million for Q4 2025, down 42.16% year-over-year from $16.8 million in Q4 2024, and up 82.11% quarter-over-quarter from $5.3 million in Q3 2025.
XBiotech (XBIT) Total Liabilities (2014 - 2026) Analysis & Trends
XBiotech's Total Liabilities history runs 12 years deep, the most recent figure standing at $9.7 million for Q4 2025.
- In Q4 2025, Total Liabilities fell 42.16% year-over-year to $9.7 million; the TTM figure through Dec 2025 stood at $9.7 million (down 42.16% YoY), while the FY2025 annual figure was $9.7 million, down 42.16% from the prior year.
- Total Liabilities for Q4 2025 stood at $9.7 million, up from $5.3 million in the prior quarter.
- The five-year high for Total Liabilities was $18.9 million in Q2 2024, with the low at $3.8 million in Q1 2021.
- The 5-year median for Total Liabilities is $6.0 million (2022), against an average of $8.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 256.17% in 2024, then sank 70.2% in 2025.
- XBiotech's Total Liabilities stood at $5.8 million in 2021, then declined by 1.57% to $5.7 million in 2022, then jumped by 36.27% to $7.8 million in 2023, then surged by 116.57% to $16.8 million in 2024, then slumped by 42.16% to $9.7 million in 2025.
- Business Quant data shows XBIT's Total Liabilities at $9.7 million in Q4 2025, $5.3 million in Q3 2025, and $5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 5.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.19 Mn |
| Dec 31, 2025 | 9.73 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 5.62 Mn |
| Mar 31, 2025 | 7.15 Mn |
| Dec 31, 2024 | 16.83 Mn |
| Sep 30, 2024 | 17.74 Mn |
| Jun 30, 2024 | 18.85 Mn |
| Mar 31, 2024 | 18.58 Mn |
| Dec 31, 2023 | 7.77 Mn |
| Sep 30, 2023 | 6.94 Mn |
| Jun 30, 2023 | 6.07 Mn |
| Mar 31, 2023 | 5.22 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 6.03 Mn |
| Jun 30, 2022 | 10.67 Mn |
| Mar 31, 2022 | 5.24 Mn |
| Dec 31, 2021 | 5.79 Mn |
| Sep 30, 2021 | 5.36 Mn |
| Jun 30, 2021 | 5.39 Mn |